1Siegel R,Ma J,Jemal A.Cancer statistics,2014[J].CA Cancer J Clin,2014,64(1):9-29.
2Forde PM,Reiss KA,Zeidan AM.What lies within:novel strategies in immunotherapy for non-small cell lung cancer[J].Oncologist,2013,18(11):1203-1213.
3Raina D,Kosugi M,Ahmad R,et al.Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells[J].Mol Cancer Ther,2011,10(5):806-816.
4Hollingsworth MA,Swanson BJ.Mucins in cancer:protection and control of the cell surface[J].Nat Rev Cancer,2004,4(1):45-60.
5Bafna S,Kaur S,Batra SK.Membrane-bound mucins:the mechanistic basis for alterations in the growth and survival of cancer cells[J].Oncogene,2010,29(20):2893-2904.
6Wurz GT,Gutierrez AM,Greenberg BE,et al.Antitumor effects of L-BLP25 antigen-specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model[J].J Transl Med,2013,11(1):64.
7Butts C,Murray N,Maksymiuk A,et al.Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer[J].J Clin Oncol,2005,23(27):6674-6681.
8Butts C,Maksymiuk A,Goss G,et al.Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine(L-BLP25):phase IIB randomized,multicenter,open-label trial[J].J Cancer Res Clin Oncol,2011,137(9):1337-1342.
9Butts C,Murray RN,Smith CJ,et al.A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer[J].Clin Lung Cancer,2010,11(6):391-395.
10Butts C,Socinski MA,Mitchell PL,et al.Tecemotide(LBLP25)versus placebo after chemoradiotherapy for stage III nonsmall-cell lung cancer(START):a randomised,double-blind,phase 3 trial[J].Lancet Oncol,2014,15(1):59-68.
